Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.

@article{Sun2011ExpressionOE,
  title={Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.},
  author={Jong-mu Sun and Myung-ju Ahn and Min Jae Park and Hui-Young Lee and Jin Seok Ahn and Seungkoo Lee and Gu Gwan Kang and Joungho Han and Young-Ik Son and C H Baek and Yong Chan Ahn and Keunchil Park},
  journal={International journal of radiation oncology, biology, physics},
  year={2011},
  volume={80 3},
  pages={655-60}
}
PURPOSE Cisplatin-based concurrent chemoradiotherapy is the standard treatment of nasopharyngeal cancer. The expression of excision repair cross-complementation group 1 (ERCC1) has been reported to be associated with resistance to platinum-based chemotherapy. We evaluated whether ERCC1 expression could predict the treatment response and survival outcome of patients with locally advanced nasopharyngeal cancer who were treated with cisplatin-based concurrent chemoradiotherapy. METHODS AND… CONTINUE READING